Alfonso Valencia Herrera

Alfonso Valencia Herrera

Barcelona Supercomputing Center - Centro Nacional de Supercomputación

Life & Medical Sciences

Computational biologist, pioneer scientist applying computer science to solve biological problems, recognized as leader in his field. Focused on the analysis of large collections of genomic data, especially protein interaction networks applied to (epi)Genomics, Cancer Biology and Precision Medicine, his group train the application of Natural Language technology to the biomedical domain. He earned a PhD in Biochemistry and Molecular Biology (UAM) plus a PostDoctoral researcher in Bioinformatics (EMBL Heid). Prof. at ICREA, Scientific Director and Director’s of Life Sciences in BSC-CNS. Head of the Spanish node of the European Infrastructure for Life-Science Information, ELIXIR. Founding member and former President of the ISCB. Elected member of the European Molecular Biology Organization (EMBO). Executive Editor of "Bioinformatics" OUP, Section Editor of Mol Oncol. Editor FEBS Letters, Prof. Honoris Causa by the Danish Technical University.

Research interests

His research interest is the development of Computational Biology methods and their application to biomedical problems. Some of the computational methods he developed are considered pioneering work in areas such as biological text mining, protein coevolution, disease networks and more recently modelling cellular systems (digital twins). He participates in some of the key cancer related international consortia. In terms of community services, he is one of the initial promoters of what is now the ELIXIR infrastructure, founder of the Spanish Bioinformatics network and founder member and former president of ISCB the professional association of Bioinformaticians and the Executive Editor of the main journal in the field (Bioinformatics OUP).

Selected publications

- Barajas A, Amengual P, Pons A, Ortiz R, Gracia O, Urrea V, de la Iglesia N, Blanco J, Anjos C, Varela I, Ferran T ... Valencia A 2024 "Virus-like particle-mediated delivery of structure-selected neoantigens demonstrates immunogenicity and antitumoral activity in mice", Journal of Translational Medicine, 22, 14
- Riba, M et al. 2024, 'The 1+Million Genomes Minimal Dataset for Cancer', Nature genetics, 56 - 733 - 736.
- Nunez-Carpintero I, Rigau M, Bosio M, O'Connor E, Spendiff S, Azuma Y, Topf A, Thompson R, 't Hoen PAC, Chamova T, Tournev I, Guergueltcheva V, Laurie S, Beltran S, Capella-Gutierrez S, Cirillo D, Lochmueller H & Valencia A 2024, 'Rare disease research workflow using multilayer networks elucidates the molecular determinants of severity in Congenital Myasthenic Syndromes', Nature communications, 15 - 1 -1227.
- Serra F, Nieto-Aliseda A, Fanlo L, Rovirosa L, Cabrera-Pasadas M, Lazarenkov A, Urmeneta B, Alcalde A, Nola E M, Okorokov A L, Fraser P, Graupera M, Castillo S D, Sardina J L, Valencia A & Javierre B M 2024, "p53 rapidly restructures 3D chromatin organization to trigger a transcriptional response", Nature Communications, Nr. 15, Art. 2821
- Nikolski M, Hovig E, Al-Shahrour F, Blomberg N, Scollen S, Valencia A & Saunders G 2024, "Roadmap for a European cancer data management and precision medicine infrastructure", Nature Cancer 5, 367-372
- Parra RG, Valencia A et al. 2024 "Frustraevo: a web server to lozalize and quantify the conservation of local energetic frustration in protein families", Nucleic Acids Research, vol 52 no W1 pp W233-W237.
- Català F, Tejedor L, Driver JA, Hutton B, Vicent J, Ridao M, Alonso A, Correa P, Fores J, Balanza V, Valencia A, Cobos I & Tabares R 2024, "Risk of cancer development associated with disease-modifying therapies for multiple sclerosis: study protocol for a systematic review and meta-analysis of randomised and non-randomised studies", BioMed Central Ltd, 13-263